Cystatin D Fibrinogen Like Protein 1

June 26, 2023 updated by: Heba abd el salam selim, Assiut University

Role of Cystatin D and Fibrinogen Like Protein 1 in Rheumatoid Arthritis and Their Relation to Disease Activity

to detect role of cystatin D and fibrinogen like protein 1 in rheumatoid arthritis asses relationship between disease activity and cystatin D and fibrinogen like protein 1

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

86

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

adult patient diagnosed with rheumatoid arthrits

Description

Inclusion Criteria:

  • adult patient diagnosed for rheumatoid arthritis

Exclusion Criteria:

  • patient with overlap syndrome indiviuals with other auto immune diseases

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
control
Diagnostic test: ELISA TEST
ELISA TEST for cystatin D and fibrinogen like protein
active disease
Diagnostic test: ELISA TEST
ELISA TEST for cystatin D and fibrinogen like protein

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
detect role of cystatin D and fibrinogen like protein 1
Time Frame: one year
detect role of the two biomarkers and there relationship to rheumatoid arthriths
one year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Assiut University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

January 1, 2024

Primary Completion (Estimated)

January 1, 2026

Study Completion (Estimated)

January 1, 2026

Study Registration Dates

First Submitted

June 26, 2023

First Submitted That Met QC Criteria

June 26, 2023

First Posted (Actual)

July 5, 2023

Study Record Updates

Last Update Posted (Actual)

July 5, 2023

Last Update Submitted That Met QC Criteria

June 26, 2023

Last Verified

June 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • cystatin D

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Fibrinogen Like Protein 1

Clinical Trials on ELISA TEST

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Singapore

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe